Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer

International Journal of Molecular Medicine

Volumn 31, Issue 1, 2013, Pages 33-42

  Ye, Sujuan ^a   Yang, Weihan ^a   Wang, Yu ^a   Ou, Wenjing ^a   Ma, Qingping ^a   Yu, Chuanjiang ^a   Ren, Jiang ^a   Zhong, Guoxing ^a   Shi, Huashan ^a   Yuan, Zhu ^a   Su, Xiaolan ^a   Zhu, Wen ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

A549; Cationic liposomes; Cisplatin; Combination treatment; Gene therapy; INOS; Lung cancer

Indexed keywords

CISPLATIN; GELATINASE A; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOSOME; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER MODEL; CANCER SIZE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE ACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO GENE TRANSFER; IN VITRO STUDY; LIPOSOMAL DELIVERY; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GENETIC THERAPY; HUMANS; LIPOSOMES; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; NITRIC OXIDE SYNTHASE TYPE II; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873155737     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1171     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Jamieson ER and Lippard SJ: Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev 99: 2467-2498, 1999.
3. Molina JR, Adjei AA and Jett JR: Advances in chemotherapy of non-small cell lung cancer. Chest 130: 1211-1219, 2006.
4. Xie K and Fidler IJ: Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev 17: 55-75, 1998.
5. Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Ding A Troso T and Nathan C: Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 256: 225-228, 1992.
6. Heller A: Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers. ChemMedChem 3: 1493-1499, 2008.
7. Lala PK and Chakraborty C: Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 3: 149-156, 2001.
8. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M and Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res 88: 1190-1198, 1997.
9. Puhakka A, Kinnula V, Näpänkangas U, Säily M, Koistinen P, Pääkkö P and Soini Y: High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma. APMIS 111: 1137-1146, 2003.
10. Fitzpatrick B, Mehibel M, Cowen RL and Stratford IJ: iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 19: 217-224, 2008.
11. Khare PD, Shao-Xi L, Kuroki M, Hirose Y, Arakawa F, Nakamura K, Tomita Y and Kuroki M: Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase. Cancer Res 61: 370-375, 2001.
12. Xu W, Liu L and Charles IG: Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J 16: 213-215, 2002.
13. Soler MN, Bobé P, Benihoud K, Lemaire G, Roos BA and Lausson S: Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J Gene Med 2: 344-352, 2000.
14. Lumniczky K and Safrany G: Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect. Pathol Oncol Res 12: 118-124, 2006.
15. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
16. Ropponen KM, Kellokoski JK, Lipponen PK, Eskelinen MJ, Alanne L, Alhava EM and Kosma VM: Expression of inducible nitric oxide synthase in colorectal cancer and its association with prognosis. Scand J Gastroenterol 35: 1204-1211, 2000.
17. Raspollini MR, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A and Taddei GL: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 92: 806-812, 2004.
18. Adams C, McCarthy HO, Coulter JA, Worthington J, Murphy C, Robson T and Hirst DG: Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. J Gene Med 11: 160-168, 2009.
19. Worthington J, McCarthy HO, Barrett E, Adams C, Robson T and Hirst DG: Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 6: 673-680, 2004.
20. Worthington J, Robson T, O'Keeffe M and Hirst DG: Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther 9: 263-269, 2002.
21. McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, McKeown SR, Hirst DG and Robson T: p21 (WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 14: 246-255, 2007.
22. Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S and Hirst DG: The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther 15: 495-503, 2008.
23. Wang Z, Cook T, Alber S, Liu K, Kovesdi I, Watkins SK, Vodovotz Y, Billiar TR and Blumberg D: Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res 64: 1386-1395, 2004.
24. Evig CB, Kelley EE, Weydert CJ, Chu Y, Buettner GR and Burns CP: Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts. Nitric Oxide 10: 119-129, 2004.
25. Wink DA, Cook JA, Christodoulou D, Krishna MC, Pacelli R, Kim S, DeGraff W, Gamson J, Vodovotz Y, Russo A and Mitchell JB: Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide 1: 88-94, 1997.
26. Son KK and Hall KJ: Nitric oxide-mediated tumor cell killing of cisplatin-based interferon-gamma gene therapy in murine ovarian carcinoma. Cancer Gene Ther 7: 1324-1328, 2000.
27. Konovalova NP, Goncharova SA, Volkova LM, Rajewskaya TA, Eremenko L and Korolev AM: Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. Nitric Oxide 8: 59-64, 2003.
28. Chen JH, Lin HH, Chiang TA, Hsu JD, Ho HH, Lee YC and Wang CJ: Gaseous nitrogen oxide promotes human lung cancer cell line A549 migration, invasion, and metastasis via iNOS-mediated MMP-2 production. Toxicol Sci 106: 364-375, 2008.
29. Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC and Malkinson AM: Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 62: 6850-6856, 2002.
30. Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, et al: Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 145: 17-25, 2010.
31. Shamimi-Noori S, Yeow W-S, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, et al: Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway. Cancer Gene Ther 15: 356-370, 2008.
32. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, Xu K, Atkinson EN, Bekele BN, Stephens LC, et al: Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11: 733-739, 2004.
33. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, et al: Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6: 1160-1166, 2000.
34. Fraser M, Chan SL, Chan SS, Fiscus RR and Tsang BK: Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene 25: 2203-2212, 2006.
35. Nguyen DM, Spitz FR, Yen N, Cristiano RJ and Roth JA: Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112: 1372-1377, 1996.
36. Cook T, Wang Z, Alber S, Liu K, Watkins SC, Vodovotz Y, Billiar TR and Blumberg D: Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res 64: 8015-8021, 2004.
37. Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T and Savaraj N: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591: 124-127, 2008.
38. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31, 2007.
39. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, et al: mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15: 5404-5413, 2009.
40. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD and Pavlakis GN: Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15: 647-652, 1997.
41. Keshamouni V, Arenberg D and Kalemkeriam G (eds): Lung Cancer Metastasis: Novel Biological Mechanisms and Impact on Clinical Practice. Springer, New York, pp1-395, 2009.
42. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-23, 2007.
43. Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR and Lala PK: Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 81: 889-896, 1999.
44. Obara H and Harasawa R: Nitric oxide causes anoikis through attenuation of E-cadherin and activation of caspase-3 in human gastric carcinoma AZ-521 cells infected with Mycoplasma hyorhinis. J Vet Med Sci 72: 869-874, 2010.
45. Bjorklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755: 37-69, 2005.
46. Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C and Dorigo O: Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 67: 535-544, 2010.
47. Urso L, Muscella A, Calabriso N, Vetrugno C, Jiménez E, Montiel M and Marsigliante S: Effects of cisplatin on matrix metalloproteinase-2 in transformed thyroid cells. Biochem Pharmacol 79: 810-816, 2010.
48. Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, Roberts DD and Wink DA: Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 19: 73-76, 2008.